![298 Feasibility study of concurrent cisplatin/etoposide (PE) and thoracic radiotherapy (TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC): Report of a Japan clinical oncology group study (JCOG-9509)]()
298 Feasibility study of concurrent cisplatin/etoposide (PE) and thoracic radiotherapy (TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC): Report of a Japan clinical oncology group study (JCOG-9509)Kubota, K.; Nishiwaki, Y.; Furuse, K.; Fukuoka, M.; Takada, M.; Ariyoshi, Y.; Kurita, Y.; Saijo, N. · Lung Cancer · 1997